- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 399-413 of
901 results
2365 Exhibit: EX2365 US Food Drug Administration, DrugsFDA, Amaryl®
Document
IPR2023-00724, No. 2365 Exhibit - EX2365 US Food Drug Administration, DrugsFDA, Amaryl® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2108 Exhibit: EX2108 Reiter Brennan, C, Comprehensive Care Models for Cardiom...
Document
IPR2023-00724, No. 2108 Exhibit - EX2108 Reiter Brennan, C, Comprehensive Care Models for Cardiometabolic Disease, Curr Cardiol Rep, 23322 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2394 Exhibit: EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type...
Document
IPR2023-00724, No. 2394 Exhibit - EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain An Online Discrete Choice Expe...
|
|
Cite Document
2381 Exhibit: EX2381 Valentine, V, Goldman, J and Shubrook, JH, Rationale for, In...
Document
IPR2023-00724, No. 2381 Exhibit - EX2381 Valentine, V, Goldman, J and Shubrook, JH, Rationale for, Initiation and Titration of the Basal InsulinGLP 1RA Fixed Ratio Combination Products, IDe...
|
|
Cite Document
2091 Exhibit: EX2091 Das, SR, et al, ACC Expert Consensus Decision Pathway on ...
Document
IPR2023-00724, No. 2091 Exhibit - EX2091 Das, SR, et al, ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and...
|
|
Cite Document
2482 Exhibit: EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide...
Document
IPR2023-00724, No. 2482 Exhibit - EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide Injection, httpswwwozempiccomhow to takeside effectshtml (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2407 Exhibit: EX2407 Victoza® Prescribing Information rev Nov 2020
Document
IPR2023-00724, No. 2407 Exhibit - EX2407 Victoza® Prescribing Information rev Nov 2020 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2431 Exhibit: EX2431 US Food Drug Administration, DrugsFDA, Oseni®
Document
IPR2023-00724, No. 2431 Exhibit - EX2431 US Food Drug Administration, DrugsFDA, Oseni® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2467 Exhibit: EX2467 US Food Drug Administration, DrugsFDA, Steglujan
Document
IPR2023-00724, No. 2467 Exhibit - EX2467 US Food Drug Administration, DrugsFDA, Steglujan (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2373 Exhibit: EX2373 Cleveland Clinic, “GLP 1 Agonists,” httpsmyclevelandclinicor...
Document
IPR2023-00724, No. 2373 Exhibit - EX2373 Cleveland Clinic, “GLP 1 Agonists,” httpsmyclevelandclinicorghealthtreatments13901 glp 1 agonists, last reviewed July 3, 2023 (P.T.A.B. Jan. 17, 20...
|
|
Cite Document
2454 Exhibit: EX2454 US Food Drug Administration, DrugsFDA, Synjardy XR
Document
IPR2023-00724, No. 2454 Exhibit - EX2454 US Food Drug Administration, DrugsFDA, Synjardy XR (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2375 Exhibit: EX2375 US Food Drug Administration, Approval Letter for Januvia® O...
Document
IPR2023-00724, No. 2375 Exhibit - EX2375 US Food Drug Administration, Approval Letter for Januvia® Oct 16, 2006 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2451 Exhibit: EX2451 US Food Drug Administration, DrugsFDA, Glyxambi
Document
IPR2023-00724, No. 2451 Exhibit - EX2451 US Food Drug Administration, DrugsFDA, Glyxambi (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2081 Exhibit: EX2081 Dani Blum, What’s Next for Ozempic, New York Times, Decem...
Document
IPR2023-00724, No. 2081 Exhibit - EX2081 Dani Blum, What’s Next for Ozempic, New York Times, December 20, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2473 Exhibit: EX2473 US Food Drug Administration, DrugsFDA, Trijardy XR
Document
IPR2023-00724, No. 2473 Exhibit - EX2473 US Food Drug Administration, DrugsFDA, Trijardy XR (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
